A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Grant

Date/time Interval

  • November 6, 2012 - November 5, 2017
  • Total Award Amount

  • 43500.00
  • Direct Costs

  • 34524.00
  • Sponsor Award Id

  • Contributor

  • Nabell M.D., Lisle   Principal Investigator